WASHINGTON – Tomorrow, April 27, the Biologics Prescribers Collaborative (BPC), a project of the Alliance for Patient Access, will host a congressional briefing on Capitol Hill to discuss the current biosimilars policy framework and its impact on prescribing, reimbursement and use. The discussion will also highlight a new white paper from BPC, “The State of Biosimilars Policy” which will be released tomorrowmorning. The briefing, attended by patient advocates, physician advocates and congressional and regulatory staff, will be held at 8:30 a.m.in room 562 of the Dirksen Senate Office Building. The briefing is open to the press.
WHO: Patient and physician advocates and congressional and regulatory staff
WHAT: Biosimilars Policy Framework Briefing on Capitol Hill
WHERE: Dirksen Senate Office Building, Room 562, Washington DC.
WHEN: Thursday, April 27, 8:30 a.m.
RSVP: Press should RSVP to [email protected]
Brian Kennedy, Executive Director of the Alliance for Patient Access, will lead the briefing, which also features perspectives from Angus Worthing, MD, American College of Rheumatology, Steven Grossman, JD, FDA regulatory expert, and Stephen Marmaras, Director of State and National Advocacy, Global Health Living Foundation.
The Biologics Prescribers Collaborative represents medical societies whose members regularly prescribe biological medicines. The group educates and makes comment on major policy issues respecting biologics and biosimilars. The Biologics Prescribers Collaborative aims to ensure that sound policies are in place to ensure prescriber and patient confidence in all biologic therapies, including biosimilars.